Protein kinase inhibitors: Contributions from structure to clinical compounds

Quarterly Reviews of Biophysics

Volumn 42, Issue 1, 2009, Pages 1-40

  Johnson, Louise N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CHIR 99021; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; ERLOTINIB; FASUDIL; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN KINASE INHIBITOR; RAPAMYCIN; ROSCOVITINE; SORAFENIB; STAUROSPORINE DERIVATIVE; SUNITINIB; TACROLIMUS; TEMSIROLIMUS; TORICEL; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOCARCINOMA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BRAIN VASOSPASM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CATALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME CONFORMATION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NONHUMAN; PANCREAS CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

ANIMALS; HUMANS; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 67649726156     PISSN: 00335835     EISSN: 14698994     Source Type: Journal    
DOI: 10.1017/S0033583508004745     Document Type: Review

References (137)

1. AZAM, M., LATEK, R. R. & DALEY, G. Q. (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112(6), 831-843. (Pubitemid 36378885)
2. BAIN, J., PLATER, L., ELLIOTT, M., SHPIRO, N., HASTIE, C.J., MCLAUCHLAN, H., KLEVERNIC, I., ARTHUR, J. S., ALESSI, D. R. & COHEN, P. (2007). The selectivity of protein kinase inhibitors: a further update. Biochemical Journal 408(3), 297-315.
3. BANASZYNSKI, L. A., LIU, C. W. & WANDLESS, T.J. (2005). Characterization of the FKBP-rapamycin-FRB ternary complex. Journal of the American Chemical Society 127(13), 4715-4721. (Pubitemid 40489629)
4. BANTSCHEFF, M., EBERHARD, D., ABRAHAM, Y., BASTUCK, S., BOESCHE, M., HOBSON, S., MATHIESON, T., PERRIN, J., RAIDA, M., RAU, C., READER, V., SWEETMAN, G., BAUER, A., BOUWMEESTER, T., HOPF, C., KRUSE, U., NEUBAUER, G., RAMSDEN, N., RICK, J., KUSTER, B. & DREWES, G. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnology 25(9), 1035-1044. (Pubitemid 47517638)
5. BARKER, A. J., GIBSON, K. H., GRUNDY, W., GODFREY, A.A., BARLOW, J.J., HEALY, M. P., WOODBURN, J. R., ASHTON, S. E., CURRY, B. J., SCARLETT, L., HENTHORN, L. & RICHARDS, L. (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & Medicinal Chemistry Utters 11(14), 1911-1914. (Pubitemid 32675316)
6. BARNEIT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., MALINOWSKI, J., McAVOY, E. M., NAHAS, D. D., ROBINSON, R. G. & HUBER, H. E. (2005). Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochemical journal 385 (Pt 2), 399-408. (Pubitemid 40165072)
7. BAUMLI, S., LOLLI, G., LOWE, E. D., TROIANI, S., RUSCONI, L., BULLOCK, A. N., DEBRECZENI, J. E., KNAPP, S. & JOHNSON, L.N. (2008). The structure of P-TEFb (CDK9/cyclin Tl), its complex with flavopiridol and regulation by phosphorylation. EMBO Journal 27(13), 1907-1918.
8. BERTHET, C., ALEEM, E., COPPOLA, V., TESSAROLLO, L. & KALDIS, P. (2003). Cdk2 knockout mice are viable. Current Biology 13(20), 1775-1785. (Pubitemid 37274109)
9. BETTAYEB, K., OUMATA, N., ECHALIER, A., FERANDIN, Y., ENDICOTT.J. A., GALONS, H. & MEIJER, L. (2008). CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 27(44), 5797-5807.
10. BIERER, B. E., MATTILA, P. S., STANDAERT, R. F., HERZENBERG, L. A., BURAKOFF, S. J., CRABTREE, G. & SCHREIBER, S. L. (1990). Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proceedings of the National Academy of Sciences USA 87(23), 9231-9235. (Pubitemid 120030599)
11. BREITENLECHNER, C., GASSEI., M., HIDAKA, H., KINZEL, V., HUBER, R., ENGH, R.A. & BOSSEMEYER, D. (2003). Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11(12), 1595-1607. (Pubitemid 37510358)
12. BYRD, J. C., LIN, T. S., DALTON, J. T., Wu, D., PHELPS, M. A., FISCHER, B., MORAN, M., BLUM, K. A., ROVIN, B., BROOKER-MCELDOWNEY, M., BROERING, S., SCHAAF, L. J., JOHNSON, A.J., LUCAS, D.M., HEEREMA, N. A., LOZANSKI, G., YOUNG, D. C., SUAREZ, J. R., COLEVAS, A. D. & GREVER, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109(2), 399-404. (Pubitemid 46105932)
13. CHAN, S. K., GULLICK, W.J. & HILL, M. E., (2006). Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. European Journal of Cancer 42(1), 17-23. (Pubitemid 41814528)
14. CHAO, S. H., FUJINAGA, K., MARION, J. E., TAUBE, R., SAUSVILLE, E. A., SENDEROWICZ, A. M., PETERLIN, B. M. & PRICE, D. H. (2000). Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. Journal of Biological Chemistiy 275(37), 28345-28348. (Pubitemid 30704157)
15. CHEN, J. & FANG, Y. (2002). A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochemical Pharmacology 64(7), 1071-1077. (Pubitemid 35247814)
16. CHO, H. S., MASON, K., RAMYAR, K. X., STANLEY, A. M., GABELLI, S. B., DENNEY JR., D.W. & LEAHY, D.J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924), 756-760. (Pubitemid 36227628)
17. CHOI, J., CHEN, J., SCHREIBER, S. L. & CLARDY, J. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273(5272), 239-242. (Pubitemid 26285890)
18. COHEN, P. (2002). Protein kinases - the major drug targets of the twenty-first century ? Nahm Reviews Drug Discovery 1(4), 309-315. (Pubitemid 37361447)
19. COSTA, L.J. & DRABKIN, H.A. (2007). Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12(12), 1404-1415.
20. DAVIES, S. P., REDDY, H., CAIVANO, M. & COHEN, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochemical Journal 351(Pt 1), 95-105. (Pubitemid 30781561)
21. DAVIES, H., BIGNELL, G. R., COX, C., STEPHENS, P., EDKINS, S., CLEGG, S., TRAGUE, J., WOFFENDIN, H., GARNETT, M. J., BOTTOMLEY, W., DAVIS, N., DICKS, E., EWING, R., FLOYD, Y., GRAY, K., HALL, S., HAWES, R., HUGHES, J., KOSMIDOU, V., MENZIES, A., MOULD, C., PARKER, A., STEVENS, C., WAIT, S., HOOPER, S., WILSON, R., JAYATILAKE, H., GUSTERSON, B. A., COOPER, C., SHIPLEY, J., HARGRAVE, D., PRITCHARD-JONES, K., MAITLAND, N., CHENEVIX-TRENCH, G., RIGGINS, G. J., BIGNER, D. D., PALMIERI, G., Cossu, A., FLANAGAN, A., NICHOLSON, A., Ho, J. W., LEUNG, S. Y., YUEN, S. T., WEBER, B. L., SEIGLER, H. F., DARROW, T. L., PATERSON, H., MARAIS, R., MARSHALL, C.J., WOOSTER, R., STRATTON, M. R. & FUTREAL, P. A. (2002a). Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954. (Pubitemid 34716871)
22. DAVIES, T. G., PRATT, D. J., ENDICOTT, J. A., JOHNSON, L. N. & NOBLE, M. E. (2002b). Structure-based design of cyclin-dependent kinase inhibitors. Pharmacology & Therapeutics 93(2-3), 125-133. (Pubitemid 34615554)
23. DE AZEVEDO JR., W. F., MUELLER-DIECKMANN, H. J., SCHULZE-GAHMEN, U., WORLAND, P. J., SAUSVILLE, E. & KIM, S. H. (1996). Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proceedings of the National Academy of Sciences USA 93(7), 2735-2740. (Pubitemid 26116234)
24. DRUKER, B.J., TAMURA, S., BUCHDUNGER, E., OHNO, S., SEGAL, G. M., FANNING, S., ZIMMERMANN, J. & LYDON, N. B. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl. positive cells. Nature Medicine 2(5), 561-566. (Pubitemid 26151518)
25. ENGEL., M., HINDIE, V., LOPEZ-GARCIA, L. A., STROBA, A., SCHAEFFER, F., ADRIAN, I., IMIG, J., IDRISSOVA, L.,
26. NASTAINCZYK, W., ZEUZEM, S., ALZARI, P. M., HARTMANN, R. W., PIIPER, A. & BIONDI, R. M. (2006). Allosteric activation of the protein kinase PDKl with low molecular weight compounds. EMBO Journal 25(23), 5469-5480. (Pubitemid 44847188)
27. FABBRO, D., RUETZ, S., BUCHDUNGER, E., COWAN-JACOB, S. W., FENDRICH, G., LIEBETANZ, J., MESTAN, J., O'REILLY, T., TRAXLER, P., CHAUDHURI, B., FRETZ, H., ZIMMERMANN, J., MEYER, T., CARAVATTI, G., FURET, P. & MANLEY, P. W. (2002). Protein, kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacology & Therapeutics 93(2-3), 79-98. (Pubitemid 34615551)
28. FABIAN, M. A., BIGGS 3RD, W. H., TREIBER, D. K., ATTERIDGE, C. E., AZIMIOARA, M. D., BENEDETTI.M. G., CARTER, T. A., CICERI, P., EDEEN, P. T., FLOYD, M., FORD, J. M., GALVIN, M., GERLACH, J. L., GROTZFELD, R. M., HERRGARD, S., INSKO, D. E., INSKO, M. A., LAI, A. G., LELIAS, J. M., MEHTA, S. A., MILANOV, Z. V., YELASCO, A. M., WODICKA, L. M., PATEL, H. K., ZARRINKAR, P.P. & LOCKHART, D.J. (2005). A small molecule-kinase interaction map for clinical, kinase inhibitors. Nature Biotechnology 23(3), 329-336.
29. FANG, Y., VILELLA-BACH, M., BACHMANN, R., FLANIGAN, A. & CHEN, J. (2001). Phosphatidic acid-mediated mitogenic activation, of mTOR signaling. Science 294(5548), 1942-1945. (Pubitemid 33101594)
30. FEDOROV, O., MARSDEN, B., POGACIC, V., RELLOS, P., MULLER, S., BULLOCK, A. N., SCHWALLER, J., SUNDSTROM, M. & KNAPP, S. (2007a). A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences USA. 104(51), 20523-20528.
31. FEDOROV, O., SUNDSTROM, M., MARSDEN, B. & KNAPP, S. (2007b). Insights for the development of specific kinase inhibitors by targeted, structural genomics. Drug Discovery Today 12(9-10), 365-372. (Pubitemid 46636375)
32. FORNIER, M. N., RATHKOPF, D., SHAH, M., PATIL, S., O'REILLY, E., TSE, A.N., HUDIS, C., LEFKOWITZ, R., KELSEN, D. P. & SCHWARTZ, G. K. (2007). Phase I dosefinding study of weekly docetaxel followed, by flavopiridol for patients with advanced solid tumors. Clinical Cancer Research 13(19), 5841-5846. (Pubitemid 47583909)
33. FOSTER, D. A. (2007). Regulation of mTOR by phosphatidic acid? Cancer Research 67(1), 1-4. (Pubitemid 46142751)
34. FRY, D. W., HARVEY, P.J., KELIER, P. R., ELLIOTT, W. L., MEADE, M., TRACHET, E., ALBASSAM, M., ZHENG, X., LEOPOLD, W. R., PRYER, N. K. & TOOGOOD, P. L. (2004). Specific inhibition of cyclin-dependent kinase 4/ 6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics 3(11), 1427-1438. (Pubitemid 39562588)
35. FUH, G., Wu, P., LIANG, W. C., ULTSCH, M., LEE, C. V., MOFFAT, B. & WIESMANN, C. (2006). Structure-function studies of two synthetic anti-vascular endothelial, growth factor Fabs and comparison with the Avastin Fab. Journal of Biological Chemistry 281(10), 6625-6631. (Pubitemid 43847597)
36. GEYER, C. E., FORSTER, J., LINDQUIST, D., CHAN, S., ROMIEU, C. G., PIENKOWSKI, T., JAGIELLO-GRUSZFELD, A., CROWN, J., CHAN, A., KAUFMAN, B., SKARLOS, D., CAMPONE, M., DAVIDSON, N., BERGER, M., OLIVA, C., RUBIN, S. D., STEIN, S. & CAMERON, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced, breast cancer. New England Journal of Medicine 355(26), 2733-2743. (Pubitemid 46021510)
37. GILES, F. J., CORTES, J., JONES, D., BERGSTROM, D., KANTARJIAN, H. & FREEDMAN, S. J. (2007). MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109(2), 500-502. (Pubitemid 46105945)
38. GILL, A. L., VERDONK, M., BOYLE, R. G. & TAYLOR, R. (2007). A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical, development. Current Topics in Medicinal Chemistry 7(14), 1408-1422. (Pubitemid 47471238)
39. GNARRA, J. R., ZHOU, S., MERRILL, M.J., WAGNER, J. R., KRUMM, A., PAPAVASSILIOU, E., OLDFIELD, E. H., KLAUSNER, R. D. & LINEHAN, W. M. (1996). Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proceedings of the National' Acadenr) of Sciences USA 93(20), 10589-10594. (Pubitemid 26333031)
40. GOMEZ, H. L., DOVAL, D. C., CHAVEZ, M. A., ANG, P. C., Aziz, Z., NAG, S., NG, C., FRANCO, S. X., CHOW, L. W., ARBUSHITES, M. C., CASEY, M. A., BERGER, M. S., STEIN, S. H. & SLEDGE, G. W. (2008). Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced, or metastatic breast cancer. Journal of Clinical Oncology 26(18), 2999-3005.
41. GREENMAN, C., STEPHENS, P., SMITH, R., DALGLIESH, G. L., HUNTER, C., BIGNELL, G., DAVIES, H., TEAGUE, J., BUTLER, A., STEVENS, C., EDKINS, S., O'MEARA, S., VASTRIK, I., SCHMIDT, E. E., Avis, T., BARTHORPE, S., BHAMRA, G., BUCK, G., CHOUDHURY, B., CLEMENTS, J., COLE. J., DICKS, E., FORBES, S., GRAY, K., HALLIDAY, K., HARRISON, R., HILLS, K., HINTON, J., JENKINSON, A., JONES, D., MENZIES, A., MIRONENKO, T., PERRY, J., RAINE, K., RICHARDSON, D., SHEPHERD, R., SMALL, A., TOFTS, C., VARIAN, J., WEBB, T., WEST, S., WIDAA, S., YATES, A., CAHILL, D. P., Louis, D. N., GOLDSTRAW, P., NICHOLSON, A. G., BRASSEUR, F., LOOIJENGA, L., WEBER, B. L., CHIEW, Y.E., DEFAZIO, A., GREAVES, M. F., GREEN, A. R., CAMPBEIL, P., BIRNEY, E., EASTON, D. F., CHENEVIX-TRENCH, G., TAN, M. H., KHOO, S. K., TEH, B. T., YUEN, S. T., LEUNG, S. Y., WOOSTER, R., FUTREAL, P. A. & STRATTON, M. R. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158. (Pubitemid 46398669)
42. HALL-JACKSON, C. A., EYERS, P. A., COHEN, P., GOEDERT, M., BOYLE, F. T., HEWITT, N., PLANT, H. & HEDGE, P. (1999). Paradoxical activation of Raf by a novel Raf inhibitor. Chemistry & Biology 6(8), 559-568. (Pubitemid 29380770)
43. HANTSCHEL, O., RIX, U. & SUPERTI-FURGA, G. (2008). Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia and Lymphoma 49(4), 615-619.
44. HUDES, G., CARDUCCI, M., TOMCZAK, P., DUTCHER, J., FIGLIN, R., KAPOOR, A., STAROSLAWSKA, E., SOSMAN, J., MCDERMOTT, D., BODROGI, I., KOVACEVIC, Z., LESOVOY, V., SCHMIDT-WOLF, I. G., BARBARASH, O., GOKMEN, E., O'TOOLE, T., LUSTGARTEN, S., MOORE, L. & MOTZER, R. J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356(22), 2271-2281. (Pubitemid 46849157)
45. HUSE, M. & KURIYAN, J. (2002). The conformational plasticity of protein kinases. Cell 109(3), 275-282. (Pubitemid 34606870)
46. JACOBS, M., HAYAKAWA, K., SWENSON, L., BELLON, S., FLEMING, M., TASLIMI, P. & DORAN, J. (2006). The structure of dimeric ROCK I reveals the mechanism for ligand. selectivity. Journal of Biological Chemistry 281(1), 260-268. (Pubitemid 43671185)
47. JOHNSON, L. N. & LEWIS, R.J. (2001). Structural basis for control by phosphorylation. Chemical Reviews 101(8), 2209-2242. (Pubitemid 35373017)
48. JOHNSON, L. N., NOBLE, M. E. & OWEN, D.J. (1996). Active and inactive protein kinases : structural basis for regulation. Cell 85(2), 149-158. (Pubitemid 26118158)
49. KARAMAN, M. W., HERRGARD, S., TREIBER, D. K., GALLANT, P., ATTERIDGB, C. E., CAMPBELL, B. T., CHAN, K. W., CICERI, P., DAVIS, M. I., EDEEN, P. T., FARAONI, R., FLOYD, M., HUNT, J. P., LOCKHART, D. J., MILANOV, Z. V., MORRISON, M. J., PALLARES, G., PATEL, H. K., PRITCHARD, S., WODICKA, L. M. & ZARRINKAR, P. P. (2008). A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology 26(1), 127-132.
50. KNIGHTON, D. R., ZHENG, J. H., TEN EYCK, L. F., ASHFORD, V. A., XUONG, N. H., TAYLOR, S. S. & SOWADSKI, J. M. (1991a). Crystal structure of the catalytic subunit of cyclic adenosine monophosphatedependent protein kinase. Science 253(5018), 407-414. (Pubitemid 21917165)
51. KNIGHTON, D. R., ZHENG, J. H., TEN EYCK, L. F., XUONG, N. H., TAYLOR, S.S. & SOWADSKI, J.M. (1991b). Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253(5018), 414-420. (Pubitemid 21917166)
52. KONTOPIDIS, G., ANDREWS, M. J., MCINNES, C., COWAN, A., POWERS, H., INNES, L., PLATER, A., GRIFFITHS, G., PATERSON, D., ZHELEVA, D. I., LANE, D. P., GREEN, S., WALKINSHAW, M. D. & FISCHER, P. M. (2003). Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure 11(12), 1537-1546. (Pubitemid 37510353)
53. KORNEV, A. P., HASTE, N. M., TAYLOR, S. S. & EYCK, L. F. (2006). Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proceedings of the National Academy of Sciences USA 103(47), 17783-17788. (Pubitemid 44852237)
54. KUMAR, A., PETRI, E. T., HALMOS, B. & BOGGON, T.J. (2008). Structure and. clinical relevance of the epidermal growth factor receptor in human cancer, Journal of Clinical Oncology 26(10), 1742-1751.
55. LA, D. S., BELZILE, J., BREADY, J. V., COXON, A., DEMELFI, T., DOERR, N., ESTRADA, J., FLYNN, J. C., FLYNN, S. R., GRACEFFA, R. F., HARRIMAN, S. P., LARROW, J. F., LONG, A.M., MARTIN, M. W., MORRISON, M.J., PATEL, V. F., ROVETO, P. M., WANG, L., WEISS, M. M., WHITTINGTON, D. A., TEFFERA, Y., ZHAO, Z., POLVERINO, A. J. & HARMANGE, J. C. (2008). Novel 2,3-dihydro-l ,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. Journal of Medicinal Chemistry 51(6), 1695-1705.
56. LACOUTURE, M. E., DESAI, A., SOLTANI, K., PETRONICROSIC, V., LAUMANN, A. E., RATAIN, M.J, & STADLER, W. M. (2006). Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clinical and Experimental Dermatology 31(6), 783-785. (Pubitemid 44563396)
57. LANDIS, M. W., PAWLYK, B. S., Li, T., SICINSKI, P. & HINDS, P. W. (2006). Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9(1), 13-22. (Pubitemid 43069507)
58. LAUDET, B., BARETTE, C., DULERY, V., RENAUDET, O., DUMY, P., METZ, A., PRUDENT, R., DESHIERE, A., DIDEBERG, O., FILHOL, O. & COCHET, C. (2007). Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochemical Journal 408(3), 363-373.
59. LAURENT-PUIC, P. & TAIEB, J. (2008). Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Current Opinion in Oncology 20(4), 454-458.
60. LE COUTRE, P., OTTMANN, O. G., GILES, F., KIM, D. W., CORTES, J., GATTERMANN, N., APPERLEY, J. F., LARSON, R. A., ABRUZZESE, E., O'BRIEN, S. G., KULICZKOWSKI, K., HOCHHAUS, A., MAHON, F. X., SAGLIO, G., GOBBI, M., KWONG, Y. L., BACCARANI, M., HUGHES, T., MARTINELLI, G., RADICH, J. P., ZHENG, M., SHOU, Y. & KANTARJIAN, H. (2008). Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with, imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111(4), 1834-1839.
61. LEROY, D. & DOERIG, C. (2008). Drugging the Plasmodium kinome: the benefits of academia-industry synergy. Trends in Pharmacological Sciences 29(5), 241-249.
62. LI, S., SCHMITZ, K. R., JEFFREY, P. D., WILTZIUS, J. J., KUSSIE, P. & FERGUSON, K. M. (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4), 301-311. (Pubitemid 40544648)
63. LIANG, J., CHOI, J. & CLARDY, J. (1999). Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallographica, Section D, Biological Crystallography 55(Pt 4), 736-744. (Pubitemid 29194519)
64. LIAO, J. J. (2007). Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. Journal of Medicinal Chemistry 50(3), 409-424. (Pubitemid 46239775)
65. LIPINSKI, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 44(1), 235-249. (Pubitemid 32239479)
66. Liu, Y. & GRAY, N. S. (2006). Rational, design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology 2(7), 358-364. (Pubitemid 43936934)
67. Lu, H. & SCHULZE-GAHMEN, U. (2006). Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. Journal of Medicinal Chemistry 49(13), 3826-3831. (Pubitemid 43967880)
68. LYNCH, T. J., BELL, D.W., SORDELI.A, R., GURUBHAGAVATULA, S., OKIMOTO, R. A., BRANNIOAN, B. W., HARRIS, P. L., HASERLAT, S. M., SUPKO, J. G., HALUSKA, F. G., Louis, D. N., CHRISTIANI, D. C., SETTLEMAN, J. & HABER, D. A. (2004). Activating mutations in the epidermal, growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 350(21), 2129-2139. (Pubitemid 38637993)
69. MALUMBRES, M., PEVARELLO, P., BARBACID, M. & BISCHOFF, J. R. (2008). CDK inhibitors in cancer therapy: what is next? Trends in Pharmacological Sciences 29(1), 16-21.
70. MANNING, G., WHYTE, D. B., MARTINEZ, R., HUNTER, T. & SUDARSANAM, S. (2002). The protein kinase complement of the human genome. Science 298(5600), 1912-1934. (Pubitemid 35425239)
71. MARONE, R., CMILJANOVIC, V., GIESE, B. & WYMANN, M. P. (2008). Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica Biophysica Acta 1784(1), 159-185.
72. MARSDEN, B. D. & KNAPP, S. (2008). Doing more than just the structure-structural, genomics in kinase drug discovery. Current Opinion in Chemical Biology 12(1), 40-45.
73. MCINNES, C., ANDREWS, M. J., ZHELEVA, D. I., LANE, D. P. & FISCHER, P. M. (2003). Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current Medicinal Chemistry. Anti-Cancer Agents 3(1), 57-69. (Pubitemid 36131635)
74. MENDEL, D. B., LAIRD, A. D., XIN, X., LOUIE, S. G., CHRISTENSEN, J. G., LI, G., SCHRECK, R. E., ABRAMS, T. J., NGAI, T. J., LEE, L. B., MURRAY, L. J., CARVER, J., CHAN, E., MOSS, K. G., HAZNEDAR, J. O., SUKBUNTHERNG, J., BLAKE, R. A., SUN, L., TANG, C., MILLER, T., SHIRAZIAN, S., MCMAHON, G. & CHERRINGTON, J. M. (2003). In vivo antitumor activity of SU11248, a novel, tyrosine kinase inhibitor targeting vascular endothelial, growth factor and platelet-derived growth factor receptors : determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 9(1), 327-337. (Pubitemid 36109749)
75. MENU, E., GARCIA, J., HUANG, X., DI LIBERTO, M., TOOGOOD, P. L., CHEN, I., VANDERKERKEN, K. & CHENKIANG, S. (2008). A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Research 68(14), 5519-5523.
76. MILANO, G., SPANO, J. P. & LEYLAND-JONES, B. (2008). EGFR-targeting drugs in combination with, cytotoxic agents: from bench to bedside, a contrasted reality. British Journal of Cancer 99(1), 1-5. (Pubitemid 351920216)
77. MOHAMMADI, M., MCMAHON, G., SUN, L., TANG, C., HIRTH, P., YEH, B. K., HUBBARD, S. R. & SCHLESSINGER, J. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276(5314), 955-960. (Pubitemid 27209095)
78. MOL, C. D., DOUGAN, D. R., SCHNEIDER, T. R., SKENE, R. J., KRAUS, M. L., SCHEIBE, D. N., SNELL, G. P., Zou, H., SANG, B. C. & WILSON, K. P. (2004). Structural, basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. Journal of Biological Chemistry 279(30), 31655-31663. (Pubitemid 39037836)
79. MOL, C. D., LIM, K. B., SRIDHAR, V., ZOU, H., CHIEN, E. Y., SANG, B. C., NOWAKOWSKI, J., KASSEL, D. B., CRONIN, C. N. & MCREE, D. E. (2003). Structure of a c-kit product complex, reveals the basis for kinase transactivation, Journal of Biological Chemistry 278(34), 31461-31464. (Pubitemid 37048320)
80. MOTZER, R.J., MICHAELSON, M. D., REDMAN, B. G., HUDES, G. R., WILDING, G., FIGLIN, R. A., GINSBERG, M. S., KIM, S. T., BAUM, C. M., DEPRIMO, S. E., Li, J. Z., BELLO, C. L., THEUER, C. P., GEORGE, D. J. & RINI, B. I. (2006). Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 24(1), 16-24. (Pubitemid 46630489)
81. MOTZER, R. J., MICHAELSON, M. D., ROSENBERG, J., BUKOWSKI, R. M., CURTI, B. D., GEORGE, D. J., HUDES, G. R., REDMAN, B. G., MARGOLIN, K. A. & WILDING, G. (2007). Sunitinib efficacy against advanced renal, cell carcinoma. The Journal of Urology 178(5), 1883-1887. (Pubitemid 47538608)
82. MOYER J. D., BARBACCI, E. G., IWATA, K. K., ARNOLD, L., BOMAN, B., CUNNINGHAM, A., DIORIO, C., DOTY, J., MORIN, M. J., MOVER, M. P., NEVEU, M., POLLACK, V. A., PUSTILNIK, L. R., REYNOLDS, M. M., SLOAN, D., THELEMAN, A. & MILLER, P. (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research 57(21), 4838-4848. (Pubitemid 27468992)
83. NAGAR, B., BORNMANN, W. G., PELLICENA, P., SCHINDLER, T., VEACH, D. R., MILLER, W. T., CLARKSON, B. & KURIYAN, J. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research 62(15), 4236-4243. (Pubitemid 34827278)
84. NAGAR, B., HANTSCHEL, O., YOUNG, M. A., SCHEFFZEK, K., VEACH, D., BORNMANN, W., CLARKSON, B., SUPERTI-FURGA, G. & KURIYAN, J. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112(6), 859-871. (Pubitemid 36378887)
85. NICHOLSON, R. I., GEE, J. M. & HARPER, M. E. (2001). EGFR and. cancer prognosis. European Journal of Cancer 37(Suppl4), S9-S15. (Pubitemid 32938124)
86. NOBLE, M. E., ENDICOTT, J. A. & JOHNSON, L. N. (2004). Protein kinase inhibitors: insights into drug design from structure. Science 303(5665), 1800-1805. (Pubitemid 38374863)
87. NOLEN, B., TAYLOR, S. & GHOSH, G. (2004). Regulation of protein kinases; controlling activity through activation segment conformation. Molecular Cell 15(5), 661-675. (Pubitemid 39194898)
88. OHREN, J. F., CHEN, H., PAVLOVSKY, A., WHITEHEAD, C., ZHANG, E., KUFFA, P., YAN, C., MCCONNELL, P., SPESSARD, C., BANOTAI, C., MUELLER, W. T., DELANEY, A., OMER, C., SEBOLT-LEOPOLD, J., DUDLEY, D. T., LEUNG, I. K., FLAMME, C., WARMUS, J., KAUFMAN, M., BARRETT, S., TECLE, H. & HASEMANN, C.A. (2004). Structures of human MAP kinase kinase 1 (MEKl) and MEK2 describe novel noncompetitive kinase inhibition. Nature Structural & Molecular Biology 11(12), 1192-1197.
89. ONO-SAITO, N., NIKI, I. & HIDAKA, H. (1999). H-series protein kinase inhibitors and potential clinical, applications. Pharmacobgy & Therapeutics 82(2-3), 123-131. (Pubitemid 29255909)
90. ORTEGA, S., PRIETO, I., ODAJIMA, J., MARTIN, A., Duisus, P., SOTILLO, R., BARBERO, J. L., MALUMBRES, M. & BARBACID, M. (2003). Cyclin-dependent kinase 2 is essential, for meiosis but not for mitotic cell division in mice. Nature Genetics 35(1), 25-31. (Pubitemid 37048592)
91. PAEZ, J. G., JANNE, P. A., LEE, J. C., TRACY, S., GREULICH, H., GABRIEL, S., HERMAN, P., KAYE, F. J., LINDEMAN, N., BOGGON, T.J., NAOKI, K., SASAKI, H., FUJII, Y., ECK, M. J., SELLERS, W. R., JOHNSON, B. E. & MEYERSON, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500. (Pubitemid 38720929)
92. PAO, W., MILLER, V., ZAKOWSKI, M., DOHERTY, J., POLITI, K., SARKARIA, I., SINGH, B., HEELAN, R., RUSCH, V., FULTON, L., MARDIS, E., KUPFER, D., WILSON, R., KRIS, M. & VARMUS, H. (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences USA 101(36), 13306-13311. (Pubitemid 39209661)
93. PARGEILIS, C., TONG, L., CHURCHILL, L., GRILLO, P. F., GILMORE, T., GRAHAM, A. G., GROB, P. M., HICKEY, E. R., Moss, N., PAV, S. & REGAN, J. (2002). Inhibition of p38 MAP kinase by utilizing a novel aliosteric binding site. Nature Structural Biology 9(4), 268-272. (Pubitemid 34289898)
94. PAWSON, T. & NASH, P. (2000). Protein-protein interactions define specificity in signal, transduction. Genes & Development 14(9), 1027-1047. (Pubitemid 30324418)
95. PIERCE, A. C., SANDRETTO, K. L. & BEMIS, G. W. (2002). Kinase inhibitors and the case for CH.O hydrogen bonds in protein-ligand binding. Proteins 49(4), 567-576.
96. POTASHMAN, M. H., BREADY, J., COXON, A., DEMELFI JR., T. M., DIPIETRO, L., DOERR, N., ELBALIM, D., ESTRADA, J., GALLANT, P., GERMAIN, J., Gu, Y., HARMANGE, J. C., KAUFMAN, S. A., KENDALL, R., KIM, J. L., KUMAR, G. N., LONG, A. M., NEERVANNAN, S., PATEL, V. F., POLVERINO, A., ROSE, P., PIAS, S., WHITTINGTON, D., ZANON, R. & ZHAO, H. (2007). Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry 50(18), 4351-4373. (Pubitemid 47378834)
97. RAVAL, A., TANNER, S. M., BYRD, J. C., ANGERMAN, E. B., PERKO, J. D., CHEN, S. S., HACKANSON, B., GREVER, M. R., LUCAS, D. M., MATKOVIC, J.J., LIN, T. S., KIPPS, T.J., MURRAY, F., WEISENBURGER, D., SANGER, W., LYNCH, J., WATSON, P., JANSEN, M., YOSHINAGA, Y., ROSENQUIST, R., DE JONG, P. J., COGGILL, P., BECK, S., LYNCH, H., DE LA CHAPELLE, A. & PLASS, C. (2007). Downregulation of death-associated protein kinase 1 (DAPKl) in chronic lymphocytic leukemia. Cell 129(5), 879-890. (Pubitemid 46813150)
98. RINI, B. I. (2008). Temsirolimus, an inhibitor of mammalian target of rapamycin. Clinical Cancer Research 14(5), 1286-1290.
99. RINI, B. I., RATHMELL, W. K. & GODLEY, P. (2008). Renal cell carcinoma. Current Opinion in Oncology 20(3), 300-306.
100. RUSNAK, D. W., AFFLECK, K., COCKERILI, S. G., STUBBERFIELD, C., HARRIS, R., PAGE, M., SMITH, K.J., GUNTRIP, S. B., CARTER, M. C., SHAW, R. J., JOWETT, A., STABLES, J., TOPLEY, P., WOOD, E. R., BRIGNOLA, P. S., KADWELL, S. H., REEP, B. R., MULLIN, R. J., ALLIGOOD, K.J., KEITH, B. R., CROSBY, R.M., MURRAY, D.M., KNIGHT, W. B., GILMER, T. M. & LACKEY, K. (2001). The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Research 61(19), 7196-7203. (Pubitemid 32946515)
101. SAMLOWSKI, W. E., WONG, B. & VOGELZANG, N.J. (2008). Management of renal, cancer in the tyrosine kinase inhibitor era : a view from 3 years on. BJU International 102(2), 162-165. (Pubitemid 351852600)
102. SCHINDLER, T., BORNMANN, W., PELLICENA, P., MILLER, W. T., CLARKSON, B. & KURIYAN, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486), 1938-1942. (Pubitemid 30704121)
103. SCHLESSINGER, J. (2000). Cell, signaling by receptor tyrosine kinases. Cell 103(2), 211-225.
104. SEBOLT-LEOPOLD, J. S. (2008). Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clinical Cancer Research 14(12), 3651-3656.
105. SEBOLT-LEOPOLD, J. S. & ENGLISH, J. M. (2006). Mechanisms of drug inhibition of signalling molecules. Nature 441(7092), 457-462. (Pubitemid 44050141)
106. SEQUIST, L. V. & LYNCH, T.J. (2008). EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annual Review of Mediane 59,429-442. (Pubitemid 351287947)
107. SEQUIST, L. V., MARTINS, R. G., SPIGEL, D., GRUNBERG, S. M., SPIRA, A., JANNE, P. A., JOSHI, V. A., MCCOLLUM, D., EVANS, T. L., MUZIKANSKY, A., KUHLMANN, G. L., HAN, M., GOLDBERG, J. S., SETTLEMAN, J., IAFRATE, A. J., ENGELMAN, J. A., HABER, D. A., JOHNSON, B. E. & LYNCH, T.J. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology 26(15), 2442-2449.
108. SHAH, M. A., KORTMANSKY, J., MOTWANI, M., DROBNJAK, M., GONEN, M., YI, S., WEYERBACHER, A., CORDONCARDO, C., LEFKOWITZ, R., BRENNER, B., O'REILLY, E., SALTZ, L., TONG, W., KELSEN, D. P. & SCHWARTZ, G. K. (2005). A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clinical Cancer Research 11(10), 3836-3845. (Pubitemid 40685604)
109. SHAPIRO, G. I. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology 24(11), 1770-1783. (Pubitemid 46628473)
110. SHIGEMATSU, H. & G.AZDAR, A. F. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer 118(2), 257-262.
111. SHOR, B., ZHANG, W. G., TORAL-BARZA, L., LUCAS, J., ABRAHAM:, R. T., GIBBONS, J. J. &Yu, K. (2008). A new pharmacologic action of CCI-779 involves FKBPl 2independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Research 68(8), 2934-2943.
112. STAMOS, J., SLIWKOWSKI, M. X. & EIGENBROT, C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of Biological Chemistry 277(48), 46265-46272. (Pubitemid 35417619)
113. TETSU, O. & MCCORMICK, F. (2003). Proliferation, of cancer cells despite CDK2 inhibition. Cancer Cell 3(3), 233-245. (Pubitemid 37443879)
114. THATCHER, N., CHANG, A., PARIKH, P., RODRIGUES PEREIRA, J., CIULEANU, T., VON PAWEL, J., THONCPRASERT, S., TAN, E. H., PEMBERTON, K., ARCHER, V. & CARROLL, K. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced, non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537. (Pubitemid 41540110)
115. TINTELNOT-BLOMLEY, M. & LEWIS, R. A. (2006). A critical appraisal of structure-based drug design. IDrugs: The Investigational Drugs Journal 9(2), 114-118. (Pubitemid 43230761)
116. TOKARSKI.J. S., NEWITT, J. A., CHANG, C.Y., CHENG, J. D., WITTEKIND, M., KIEFER, S. E., KISH, K., LEE, F. Y., BORZILLERRI, R., LOMBARDO, L. J., XlE, D., ZHANG, Y. & KLEI, H. E. (2006). The structure of Dasatinib (BMS354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research 66(11), 5790-5797.3 (Pubitemid 43927133)
117. TOOGOOD, P. L., HARVEY, P. J., REPINE, J. T., SHEEHAN, D.J., VANDERWEL, S.N., ZHOU, H., KELLER, P. R., MCNAMARA, D.J., SHERRY, D., ZHU, T., BRODFUEHRER, J., CHOI, C., BARVIAN, M. R. & FRY, D. W. (2005). Discovery of a potent and selective inhibitor of cyclindependent kinase 4/6. Journal of Medicinal Chemistry 48 (7), 2388-2406. (Pubitemid 40516432)
118. TSB, A.N., CARVAJAL, R. & SCHWARTZ, G. K. (2007). Targeting checkpoint kinase 1 in cancer therapeutics. Clinicai Cancer Research 13(7), 1955-1960. (Pubitemid 46649860)
119. VAJPAI, N., STRAUSS, A., FENDRICH, G., COWAN-JACOB, S. W., MANLEY, P. W., GRZESIEK, S. & JAHNKE, W. (2008). Solution conformations and dynamics of ABL kinase inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. Journal of Biological Chemistry 283(26), 18292-18302.
120. VAN DUYNE, G. D., STANDAERT, R. F., KARPLUS, P. A., SCHREIBER, S. L. & GARDY, J. (1991). Atomic structure of FKBP-FK506, an immunophilin- immunosuppressant complex. Science 252(5007), 839-842. (Pubitemid 121000524)
121. VEVERKA, V., CRABBE, T., BIRD, I., LENNIE, G., MUSKETT, F. W., TAYLOR, R. J. & CARR, M. D. (2008). Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation, of mTOR. Oncogene 27(5), 585-595. (Pubitemid 351158903)
122. VIETH, M., SUTHERLAND, J.J., ROBERTSON, D.H. & CAMPBELL, R. M. (2005). Kinomics: characterizing the therapeutically validated kinase space. Drug Discovery Today 10(12), 839-846. (Pubitemid 40824738)
123. WAN, P. T., GARNETT, M.J., ROE, S. M., LEE, S., NICULESCU-DUVAZ, D., GOOD, V. M., JONES, C. M., MARSHALL, C. J., SPRINGER, C. J., BARFORD, D. & MARAIS, R. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6), 855-867. (Pubitemid 38410730)
124. WEISBERG, E., MANLEY, P. W., BREITENSTEIN, W., BRUGGEN, J., COWAN-JACOB, S. W., RAY, A., HUNTLY, B., FABBRO, D., FENDRICH, G., HALL-MEYERS, E., KUNG, A. L., MESTAN, J., DALEY, G. Q., CALLAHAN, L., CATLEY, L., CAVAZZA, C., AZAM, M., NEUBERG, D., WRIGHT, R. D., GILLILAND, D. G. & GRIFFIN, J. D. (2005). Characterization of AMNl07, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2), 129-141. (Pubitemid 40248339)
125. WILHELM, S. M., CARTER, C., TANG, L., WILKIE, D., MCNABOLA, A., RONG, H., CHEN, C., ZHANG, X., VINCENT, P., MCHUGH, M., CAO, Y., SHUJATH, J., GAWLAK, S., EVELEIGH, D., ROWLEY, B., LIU, L., ADNANE, L., LYNCH, M., AUCLAIR, D., TAYLOR, I., GEDRICH, R., VOZNESENSKY, A., RIEDL, B., POST, L. E., BOLLAG, G. & TRAIL, P. A. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64(19), 7099-7109. (Pubitemid 39331023)
126. WISSNER, A. & MANSOUR, T. S. (2008). The development of HKI-272 and related compounds for the treatment of cancer. Archiv der Pharmazie 341(8), 465-477.
127. WOOD, E. R., TRUESDALE, A. T., MCDONALD, O. B., YUAN, D., HASSELL, A., DICKERSON, S. H., ELLIS, B., PENNISI, C., HORNE, E., LACKEY, K., ALLIGOOD, K. J., RUSNAK, D. W., GILMER, T. M. & SHEWCHUK, L. (2004). A unique structure for epidermal, growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Research 64(18), 6652-6659. (Pubitemid 39297926)
128. WULLSCHLEGER, S., LOEWITH, R. & HALL, M. N. (2006). TOR signaling in growth and metabolism. Cell 124(3), 471-484. (Pubitemid 43199434)
129. WYATT, P. G., WOODHEAD, A. J., BERDINI, V., BOULSTRIDGE, J. A., CARR, M. G., CROSS, D. M., DAVIS, D. J., DEVINE, L. A., EARLY, T. R., FELTELL, R. E., LEWIS, E. J., MCMENAMIN, R. L., NAVARRO, E. F., O'BRIEN, M. A., O'REILLY, M., REULB, M., SAXTY, G., SEAVERS, L. C., SMITH, D. M., SQUIRES, M. S., TREWARTHA, G., WALKER, M. T. & WOOLFORD, A.J. (2008). Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1Hpyrazole-3-carboxamide (AT7519), a novel, cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based, drug design. Journal of Medicinal Chemistry 51(16), 4986-4999.
130. YIN, L., MORISHIGE, K., TAKAHASHI, T., HASHIMOTO, K., OGATA, S., TSUTSUMI, S., TAKATA, K., OHTA, T., KAWAGOE, J., TAKAHASHI, K. & KURACHI, H. (2007). Fasudil. inhibits vascular endothelial growth factorinduced angiogenesis in vitro and in vivo. Molecular Cancer Therapeutics 6(5), 1517-1525. (Pubitemid 46954018)
131. YING, Q. L., WRAY, J., NICHOLS, J., BATLLE-MORERA, L., DOBLE, B., WOODGETT, J., COHEN, P. & SMITH, A. (2008). The ground, state of embryonic stem cell selfrenewal. Nature 453(7194), 519-523. (Pubitemid 351733324)
132. Yu, Q., GENG, Y. & SICINSKI, P. (2001). Specific protection against breast cancers by cyclin Dl ablation. Nature 411(6841), 1017-1021. (Pubitemid 32612319)
133. YUAN, T. L. & CANTLEY, L. G (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510.
134. YUN, C. H., BOGGON, T. J., Li, Y., Woo, M. S., GREULICH, H., MEYERSON, M. & ECK, M. J. (2007). Structures of lung cancer-derived EGFR mutants and. inhibitor complexes: mechanism, of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3), 217-227. (Pubitemid 46349842)
135. YUN, C. H., MENGWASSER, K. E., TOMS, A. V., WOO, M. S., GREULICH, H., WONG, K. K., MEYERSON, M. & ECK, M.J. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences USA 105(6), 2070-2075.
136. ZHANG, X., GUREASKO, J., SHEN, K., COLE, P. A. & KURIYAN, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal, growth factor receptor. Cell 125(6), 1137-1149. (Pubitemid 43866200)
137. ZHANG, X., PICKIN, K. A., BOSE, R., JURA, N., COLE, P.A. SCKURIYAN, J. (2007). Inhibition, of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450(7170), 741-744. (Pubitemid 350207680)